Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Characterizing viral entry proteins in emerging variants of Chikungunya virus from the 2020 Cambodia epidemic
EF 2023-24
Résumé
Chikungunya virus (CHIKV) is an emerging mosquito-borne virus that causes chronic debilitating muscle and joint pain for months to years, and has been responsible for several epidemics in the Americas and Asia. With an expanding geographical distribution of CHIKV-carrying mosquitoes and no approved vaccine or therapeutics, the significant economic and healthcare burden posed by current and future epidemics necessitates further understanding of the molecular basis of CHIKV evolution and immune escape. We aim to determine how CHIKV re-emerged in Cambodia, in 2020, nine years after the resolution of a preceding epidemic. E1 and E2 are viral proteins that mediate CHIKV entry into a cell and mutations in these factors are well-documented in CHIKV epidemics. We hypothesize that mutations within E1 and E2 of the 2020 CHIKV strain are responsible for poor neutralization activity of antibodies generated by memory B cells from the 2011 CHIKV outbreak. CHIKV virus-like particles (VLP) are replication-incompetent but can express E1 and E2 in identical conformations to live virus. We will construct VLPs that express different mutations in E1/E2 (from 2011 and 2020 CHIKV strains), and green fluorescent protein markers. Neutralizing antibodies from the sera of individuals infected in 2011 will be assessed in the extent to which they block infection by various VLPs, by evaluating differences in intracellular fluorescent signals between the two groups. Primary human cell lines (fibroblasts, muscle cells) will be infected with live E1/E2 CHIKV mutants to evaluate differences in the innate response. The results of this study will provide novel insight into the antigenicity of CHIKV, which could inform downstream efforts to produce antibody therapeutics for emerging variants.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
505894
Name
Boghici Dan T
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing viral entry proteins in emerging variants of Chikungunya virus from the 2020 Cambodia epidemic
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chikungunya; Emerging Virus; Epidemic; Fibroblast; Humoral Immunity; Myocyte; Neutralizing Antibody; Viral Genetics; Viral Pathogenesis; Virus-Like Particle
Abstract
Chikungunya virus (CHIKV) is an emerging mosquito-borne virus that causes chronic debilitating muscle and joint pain for months to years, and has been responsible for several epidemics in the Americas and Asia. With an expanding geographical distribution of CHIKV-carrying mosquitoes and no approved vaccine or therapeutics, the significant economic and healthcare burden posed by current and future epidemics necessitates further understanding of the molecular basis of CHIKV evolution and immune escape. We aim to determine how CHIKV re-emerged in Cambodia, in 2020, nine years after the resolution of a preceding epidemic. E1 and E2 are viral proteins that mediate CHIKV entry into a cell and mutations in these factors are well-documented in CHIKV epidemics. We hypothesize that mutations within E1 and E2 of the 2020 CHIKV strain are responsible for poor neutralization activity of antibodies generated by memory B cells from the 2011 CHIKV outbreak. CHIKV virus-like particles (VLP) are replication-incompetent but can express E1 and E2 in identical conformations to live virus. We will construct VLPs that express different mutations in E1/E2 (from 2011 and 2020 CHIKV strains), and green fluorescent protein markers. Neutralizing antibodies from the sera of individuals infected in 2011 will be assessed in the extent to which they block infection by various VLPs, by evaluating differences in intracellular fluorescent signals between the two groups. Primary human cell lines (fibroblasts, muscle cells) will be infected with live E1/E2 CHIKV mutants to evaluate differences in the innate response. The results of this study will provide novel insight into the antigenicity of CHIKV, which could inform downstream efforts to produce antibody therapeutics for emerging variants.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Boghici, Dan T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~